NCT00220636 - Abilify as an Adjunctive Treatment for Refractory Depression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

January 31, 2008

Conditions

Depressive Disorder, Major

Interventions

DRUG

Aripiprazole

Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.

Trial Locations (1)

10032

Depression Evaluation Service, NY State Psychiatric Institute, New York